Investors in Halozyme Therapeutics, Inc. HALO need to pay close attention to the stock based on moves in the options market lately. That is because the Dec 15, 2017 $12.00 Call had some of the highest implied volatility of all equity …
Woodford Investment Management is understood not to be the key investor seeking Chinese approval. The stock, which is down 92% over the last year, makes up a small position in Woodford's funds, at 0.03% of the income fund and 0.1% of …
Halozyme Therapeutics, Inc. HALO was a big mover last session, as the company saw its shares rise almost 18% on the day. The upside was driven after the company announced robust phase 2 results for its pancreatic cancer drug, …
Halozyme Therapeutics, Inc. HALO was a big mover last session, as the company saw its shares rise almost 8% on the day. The stock rallied after Piper Jaffray raised its price target on the stock from $15 to $18 on "increased conviction" in …